Table 1.
Demographic and clinical data of patients and healthy control subjects
| Early AMD eyes (n = 48) | P-valuea | Control eyes (n = 42) | P-valueb | |||
|---|---|---|---|---|---|---|
| All | CD (n = 28) | SDD (n = 20) | ||||
| Age (years) | 77.5 ± 5.7 | 77.1 ± 6.6 | 78.0 ± 4.3 | 0.6c | 76.9 ± 5.7 | 0.6c |
| Gender (m/f) | 23/25 | 16/12 | 7/13 | 0.2d | 16/26 | 0.4d |
| Spherical equivalent (dioptres) | +0.5 ± 1.3 | +0.6 ± 1.6 | +0.5 ± 0.9 | 0.7c | +0.8 ± 1.7 | 0.4c |
| Phakic/Pseudophakic | 24/24 | 13/15 | 11/9 | 0.8d | 23/19 | 0.7d |
| Axial length (mm) | 23.5 ± 1.1 | 23.5 ± 0.9 | 23.5 ± 1.4 | 0.8c | 23.7 ± 0.5 | 0.3c |
| BCVA (logMAR) | +0.08 ± 0.1 | +0.06 ± 0.1 | +0.1 ± 0.2 | 0.4c | +0.006 ± 0.07 | 0.0001c |
BCVA best-corrected visual acuity
aData analysis results comparing eyes with conventional drusen (CD) vs. eyes with subretinal drusenoid deposits (SDD)
bData analysis results comparing eyes with age-related macular degeneration (AMD) vs. control eyes
cUnpaired t-test with Levene’s correction
dFisher’s exact test